ORIENT BIO Inc. (002630.KS)
KRW 1430.0
(-13.07%)
KRW 1430.0
(-13.07%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 3.03 Billion KRW | 258.56% |
| 2022 | 847.75 Million KRW | -88.54% |
| 2021 | 7.39 Billion KRW | -8.76% |
| 2020 | 8.1 Billion KRW | 12.32% |
| 2019 | 7.21 Billion KRW | -12.51% |
| 2018 | 8.24 Billion KRW | -87.14% |
| 2017 | 64.14 Billion KRW | 24.08% |
| 2016 | 51.69 Billion KRW | -11.66% |
| 2015 | 58.51 Billion KRW | -0.12% |
| 2014 | 58.59 Billion KRW | 3.77% |
| 2013 | 56.46 Billion KRW | 0.07% |
| 2012 | 56.42 Billion KRW | 15.14% |
| 2011 | 49 Billion KRW | 314.25% |
| 2010 | 11.82 Billion KRW | -65.38% |
| 2009 | 34.16 Billion KRW | 5.1% |
| 2008 | 32.51 Billion KRW | -12.84% |
| 2007 | 37.3 Billion KRW | 56.46% |
| 2006 | 23.84 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 3.04 Billion KRW | 0.28% |
| 2023 Q4 | 3.03 Billion KRW | 472.4% |
| 2023 FY | 3.03 Billion KRW | 258.56% |
| 2023 Q1 | 386.07 Million KRW | -54.46% |
| 2023 Q2 | 304.25 Million KRW | -21.19% |
| 2023 Q3 | 531.04 Million KRW | 74.54% |
| 2022 Q4 | 847.75 Million KRW | -9.01% |
| 2022 Q1 | 7.3 Billion KRW | 0.0% |
| 2022 Q3 | 931.68 Million KRW | -60.05% |
| 2022 Q2 | 2.33 Billion KRW | -68.05% |
| 2022 FY | 847.75 Million KRW | -88.54% |
| 2021 Q2 | 7.5 Billion KRW | -1.75% |
| 2021 FY | 7.39 Billion KRW | -8.76% |
| 2021 Q1 | 7.63 Billion KRW | -5.79% |
| 2021 Q3 | 7.27 Billion KRW | -3.1% |
| 2020 Q1 | 7.91 Billion KRW | 9.71% |
| 2020 Q4 | 8.1 Billion KRW | -13.0% |
| 2020 Q3 | 9.31 Billion KRW | -2.62% |
| 2020 Q2 | 9.56 Billion KRW | 20.85% |
| 2020 FY | 8.1 Billion KRW | 12.32% |
| 2019 Q3 | 6.64 Billion KRW | -0.1% |
| 2019 Q1 | 6.8 Billion KRW | -17.5% |
| 2019 Q2 | 6.65 Billion KRW | -2.23% |
| 2019 FY | 7.21 Billion KRW | -12.51% |
| 2019 Q4 | 7.21 Billion KRW | 8.59% |
| 2018 Q3 | 52.68 Billion KRW | 1.73% |
| 2018 FY | 8.24 Billion KRW | -87.14% |
| 2018 Q4 | 8.24 Billion KRW | -84.34% |
| 2018 Q2 | 51.78 Billion KRW | -5.37% |
| 2018 Q1 | 54.72 Billion KRW | -14.69% |
| 2017 FY | 64.14 Billion KRW | 24.08% |
| 2017 Q1 | 65.17 Billion KRW | 26.06% |
| 2017 Q4 | 64.14 Billion KRW | 16.23% |
| 2017 Q2 | 58.22 Billion KRW | -10.66% |
| 2017 Q3 | 55.18 Billion KRW | -5.21% |
| 2016 Q2 | 53.18 Billion KRW | -3.82% |
| 2016 Q1 | 55.29 Billion KRW | -5.51% |
| 2016 Q4 | 51.69 Billion KRW | -4.67% |
| 2016 Q3 | 54.23 Billion KRW | 1.97% |
| 2016 FY | 51.69 Billion KRW | -11.66% |
| 2015 FY | 58.51 Billion KRW | -0.12% |
| 2015 Q1 | 60.78 Billion KRW | 3.75% |
| 2015 Q4 | 58.51 Billion KRW | -7.23% |
| 2015 Q2 | 55.44 Billion KRW | -8.79% |
| 2015 Q3 | 63.08 Billion KRW | 13.77% |
| 2014 FY | 58.59 Billion KRW | 3.77% |
| 2014 Q4 | 58.59 Billion KRW | -0.94% |
| 2014 Q1 | 54.83 Billion KRW | -2.89% |
| 2014 Q2 | 56.4 Billion KRW | 2.88% |
| 2014 Q3 | 59.14 Billion KRW | 4.85% |
| 2013 Q2 | 59.62 Billion KRW | 4.85% |
| 2013 FY | 56.46 Billion KRW | 0.07% |
| 2013 Q4 | 56.46 Billion KRW | -4.0% |
| 2013 Q3 | 58.81 Billion KRW | -1.36% |
| 2013 Q1 | 56.86 Billion KRW | 0.78% |
| 2012 FY | 56.42 Billion KRW | 15.14% |
| 2012 Q4 | 56.42 Billion KRW | 0.0% |
| 2011 FY | 49 Billion KRW | 314.25% |
| 2011 Q3 | 9.29 Billion KRW | -7.16% |
| 2011 Q2 | 10.01 Billion KRW | 115.22% |
| 2011 Q1 | 4.65 Billion KRW | 0.0% |
| 2010 Q2 | 24.05 Billion KRW | 0.21% |
| 2010 Q3 | 3.48 Billion KRW | -85.49% |
| 2010 FY | 11.82 Billion KRW | -65.38% |
| 2010 Q1 | 24 Billion KRW | 0.0% |
| 2009 Q2 | 23.89 Billion KRW | -15.2% |
| 2009 FY | 34.16 Billion KRW | 5.1% |
| 2009 Q3 | 21.78 Billion KRW | -8.84% |
| 2009 Q1 | 28.18 Billion KRW | 0.0% |
| 2008 Q2 | 15.05 Billion KRW | -37.66% |
| 2008 FY | 32.51 Billion KRW | -12.84% |
| 2008 Q3 | 27.93 Billion KRW | 85.51% |
| 2008 Q1 | 24.15 Billion KRW | 0.0% |
| 2007 Q2 | 23.24 Billion KRW | -82.37% |
| 2007 Q1 | 131.89 Billion KRW | 0.0% |
| 2007 Q3 | 24.81 Billion KRW | 6.73% |
| 2007 FY | 37.3 Billion KRW | 56.46% |
| 2006 FY | 23.84 Billion KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Green Cross Holdings Corporation | 1280.16 Billion KRW | 99.763% |
| Green Cross Holdings Corporation | 724.02 Billion KRW | 99.58% |
| Pharmicell Co., Ltd. | 3.02 Billion KRW | -0.396% |
| Green Cross Corporation | 724.02 Billion KRW | 99.58% |
| GeneOne Life Science, Inc. | 17.15 Billion KRW | 82.286% |
| Celltrion, Inc. | 1890.42 Billion KRW | 99.839% |
| Samsung Biologics Co.,Ltd. | 1909.33 Billion KRW | 99.841% |
| SK bioscience Co.,Ltd. | 20.57 Billion KRW | 85.225% |
| SK Biopharmaceuticals Co., Ltd. | 178.05 Billion KRW | 98.293% |
| Prestige BioPharma Limited | 89.66 Billion KRW | 96.61% |